| mRNA |
selumetinib:piperlongumine (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0037 |
0.9 |
| mRNA |
brivanib |
CTRPv2 |
pan-cancer |
AAC |
-0.0037 |
0.9 |
| mRNA |
BYL-719 |
CTRPv2 |
pan-cancer |
AAC |
0.0045 |
0.9 |
| mRNA |
GSK4112 |
CTRPv2 |
pan-cancer |
AAC |
0.0038 |
0.9 |
| mRNA |
Dasatinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0038 |
0.9 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0033 |
0.9 |
| mRNA |
YK 4-279 |
CTRPv2 |
pan-cancer |
AAC |
0.0031 |
0.9 |
| mRNA |
pifithrin-alpha |
CTRPv2 |
pan-cancer |
AAC |
0.0036 |
0.9 |
| mRNA |
cediranib |
CTRPv2 |
pan-cancer |
AAC |
0.0052 |
0.9 |
| mRNA |
TPCA-1 |
CTRPv2 |
pan-cancer |
AAC |
-0.0029 |
0.9 |